Feds Say They Need Time to Decide Whether to Appeal Ruling in Novartis and United Therapeutics 340B Cases

The federal government told U.S. District Judge Dabney Friedrich it needs more time to decide whether to appeal her joint ruling in Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

The federal government on Wednesday told the judge that ruled against it in drug makers Novartis and United Therapeutics’ (UT) 340B contract pharmacy lawsuits it needs more “time to decide whether to file appeals.”

The government’s Dec. 1 statement about

Read More »

HRSA Audit Finds Drug Maker and Subsidiary Overcharged 340B Providers

Generic drug manufacturer Precision Dose and its subsidiary Tagi Pharma overcharged 340B covered entities, a HRSA audit found.

Precision Dose, a maker of liquid generic drugs in unit-dose syringes and cups, and Tagi Pharma, a wholly owned subsidiary that makes generic oral and injectable drugs, will have to repay 340B covered entities for overcharges following an 340B program

Read More »

Lilly and Feds Disagree Over Whether 340B Case Is Ripe for Appeal

Drug maker Lilly and the federal government disagree over Lilly's 340B contract pharmacy appeal to U.S. Seventh Circuit Court of Appeals.

Drug manufacturer Lilly and the federal government disagree over whether a federal district judge’s recent decision in Lilly’s 340B contract pharmacy case is ripe for review.

Last month, the U.S. Seventh Circuit Court of Appeals questioned whether U.S. Senior

Read More »

Supreme Court May Upend Medicare DSH Calculation Formula, Which Would Impact 340B Stakeholders

The U.S. Supreme Court heard a case this week about the Medicare disproportionate share (DSH) adjustment percentage calculation—a 340B eligibility criterion for hospitals.

340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.

On Monday, the justices heard the case of

Read More »

News Alert: U.S. Supreme Court Justices Question CMS’s Legal Basis for Slashing 340B Hospitals’ Drug Reimbursement

The U.S. Supreme Court heard arguments today about the legality of the nearly 30% Medicare Part B drug payment cut for 340B hospitals.

Several U.S. Supreme Court justices asked during a hearing today whether the Centers for Medicare & Medicaid Services (CMS) had statutory authority to single out 340B hospitals for a nearly 30% cut in Medicare Part B drug reimbursement beginning in

Read More »

340B Providers Take Center Stage Before U.S. Supreme Court Today

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging CMS's nearly 30% cut in 340B hospitals' drug reimbursement.

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging the nearly 30% cut since 2018 in what Medicare Part B pays hospitals for 340B-purchased physician administered drugs.

Arguments in American Hospital Association v. Becerra are due

Read More »

U.S. House GOP Conference Chair Stefanik Backs Protecting 340B Hospitals from Losing Eligibility During Pandemic

U.S. House GOP Conference Chair Elise Stefanik (N.Y.) is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Elise Stefanik, the third highest-ranking Republican in the U.S. House, is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Stefanik (R-N.Y.) announced her co-sponsorship of Reps. Doris

Read More »

Peter Welch, Long-Time 340B Advocate in the U.S. House, Announces Run for Senate

U.S. Rep. Peter Welch (D-Vt.), a long-time 340B advocate, is running for the U.S. Senate next year.

U.S. Rep. Peter Welch (D-Vt.), who has backed 340B covered entities in several policy battles, is running to succeed his fellow Democrat Patrick Leahy in the U.S. Senate.

Senate President Pro Tempore Leahy, 81, announced on Nov. 15 that he

Read More »

HRSA Weighs in on Recent 340B Contract Pharmacy Court Decisions

HRSA says it is pleased with two court decision regarding the 340B contract pharmacy program, but "respectfully disagrees with” and “continues to evaluate its options” about a third decision.

The U.S. Health Resources and Services Administration (HRSA) said this morning it “respectfully disagrees with” and “continues to evaluate its options” about a federal district judge’s Nov. 5 finding that drug manufacturers Novartis and United Therapeutic’s 340B contract pharmacy policies

Read More »

Carole Johnson Appears to be Leading Candidate to Run HRSA

A screen capture of a video of White House COVID-19 Testing Coordinator Carole Johnson during a briefing on the pandemic. Johnson reportedly will be named the next HRSA administrator.

After a 10-month delay, it looks like we may be getting close to the appointment of a permanent leader of the U.S. Health Resources and Services Administration (HRSA), the federal agency that runs the 340B drug pricing program.

News organization

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report